Ritholtz Wealth Management’s Krystal Biotech KRYS Stock Holding History

Ritholtz Wealth Management’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$261K	Buy	+701	New	+$209K	﹤0.01%	1120
2021 Q2	–	Sell	-3,500	Closed	-$270K	–	550
2021 Q1	$270K	Buy	+3,500	New	+$254K	0.02%	337
2020 Q4	–	Sell	-7,000	Closed	-$301K	–	418
2020 Q3	$301K	Sell	7,000 -3,200	-31%	-$139K	0.03%	209
2020 Q2	$422K	Buy	10,200 +1,200	+13%	+$57.7K	0.05%	129
2020 Q1	$389K	Buy	9,000 +1,000	+13%	+$52.3K	0.06%	90
2019 Q4	$443K	Hold	8,000	–	–	0.06%	89
2019 Q3	$278K	Sell	8,000 -11,409	-59%	-$510K	0.05%	110
2019 Q2	$782K	Hold	19,409	–	–	0.13%	53
2019 Q1	$639K	Buy	19,409 +5,000	+35%	+$118K	0.12%	64
2018 Q4	$299K	Buy	+14,409	New	+$302K	0.07%	95

Other funds holding KRYS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Ritholtz Wealth Management's KRYS Position: Q2 2026 in Review

Ritholtz Wealth Management opened a new position in Krystal Biotech (KRYS) in Q2 2026: 701 shares worth $261K. The stake represents ﹤0.01% of the portfolio and ranks #1120 among its holdings. This is a return to the name: Ritholtz Wealth Management previously reported a position in KRYS as recently as Q1 2021.

Ritholtz Wealth Management first reported a position in KRYS in Q4 2018 and has held it in 10 quarters since. The position peaked at $782K in Q2 2019. 424 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

Ritholtz Wealth Management held 701 shares of Krystal Biotech worth $261K as of Q2 2026.
Krystal Biotech was a new Ritholtz Wealth Management position in Q2 2026.
Krystal Biotech made up ﹤0.01% of Ritholtz Wealth Management's portfolio in Q2 2026, its #1120 holding.
Ritholtz Wealth Management first reported a position in Krystal Biotech in Q4 2018 and has held it in 10 quarters since.
Ritholtz Wealth Management's Krystal Biotech position peaked at $782K in Q2 2019.
424 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Ritholtz Wealth Management's 13F filing for Q2 2026, filed 10 Aug 2026.